The Food and Drug Administration (FDA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) met on Tuesday to optimize the facilitated review pathway (FRP) to expedite access to essential ...
Recent data shows Japan’s PMDA New Active Substance median approval time is faster than the US FDA, with clinical trial start-up times of around 5 months, similar to Australia, Korea ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback